In our study, the anti-tumor effect of the doxorubicin/GTN combination was correlated with a decrease in the expression of s100a9 (in tumors) and iNOS (in MDSCs), and with a decrease in PMN-MDSCs immunosuppressive function. The gene discussed is NOS2; the disease is neoplasm.